Articles
Pharma gets social – LillyPad provides platform for Lilly's corporate engagement

Pharma gets social – LillyPad provides platform for Lilly's ...

In his latest article, Daniel Ghinn explores the processes behind the launch of LillyPad and speaks with Greg Kueterman, from Lilly, on his experiences in getting the regulatory team on board and looking after the social media channels. It is almost two years since Lilly took its first deliberate steps into corporate engagement via social media with the launch of its...

Articles
FDA guidelines and social media for the pharma industry

FDA guidelines and social media for the pharma industry

Rodica Ceslov explores the challenge of meeting regulatory compliance with regards to social media use within the pharmaceutical. The challenge associated with social media and the pharmaceutical industry is how to meet regulatory compliance while utilizing this...

Articles
HR in emerging markets – cultural learnings for the benefit of a business...

HR in emerging markets – cultural learnings for the benefit ...

Alan Dixon provides a light-hearted take on the comparisons between business strategies in the west, with those in emerging markets. Not quite the politically correct start to an article on “emerging” or should we say “fast developing” markets...but one that recognises that...

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Editor's Picks

  1. Boehringer forges $7bn alliance with China's SBP Group News
  2. Lilly partners with Hims & Hers on obesity drug sales
  3. UK women's health firm Theramex sold for around £2.2bn
  4. What do midterms mean for Trump's pharma and health agenda?
  5. NICE backs Keytruda/Padcev combo for bladder cancer

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more